Replies to post #635 on Clinuvel Pharmaceuticals (CLVLY)

[MinnieM]

Where on the site are you seeing Latin? I haven't run across it.

Overall, the stock has done very well over the past year. Wish I'd held onto my position.





In Reply to 'FarmaZutical'
The new logo is absolutely horrible. And the website is overloaded and difficult to navigate. Not to mention the Latin crap.

But the product is still the same and it’s a winner.

It seems, Vitiligo is still in their radar. They post a lot about it on FB and Instagram.

Down the road we might see Scenesse being trial for a range of CNS disorders. In a recent patent filing they mention Multiple Sclerosis, Alzheimer's Disease and other dementias, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS) and which is also called Lou Gehrig's Disease, Huntington's Disease, Degenerative Nerve Diseases, Encephalitis, Epilepsy, Genetic Brain Disorders, Head and Brain Malformations, Hydrocephalus, Stroke, and Prion Diseases.

Here and now focus is on the NDA for EPP and then probably Vitiligo.

EPP alone warrants a much higher pps.

[Jestiron]

Agreed. I am here as a loyal investor for the long haul. I discovered "Epitan" after an exceptional sun poisoning event over a decade ago. Fair skinned, I still need the prophylactic benefits... will never come. I still see the tremendous benefits to EPP patients... who I sympathize with after my battles with the sun.

Good luck to us!
Jest